triazoles has been researched along with pep005 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, I; Dandekar, S; Fenton, A; Hildreth, JE; Jiang, G; Kaiser, P; Melcher, GP; Mendes, EA; Tang, Y; Thompson, GR; Wong, DP; Wong, JK | 1 |
| Campbell, M; Dandekar, S; Davis, RR; Izumiya, Y; Jiang, G; Li, Y; Lyu, Y; Maverakis, E; Nakano, K; Olney, L; Shimoda, M; Tepper, CG; Tran, K; Zhou, F | 1 |
2 other study(ies) available for triazoles and pep005
| Article | Year |
|---|---|
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation.
Topics: Azepines; Diterpenes; HIV Infections; HIV-1; Humans; I-kappa B Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Positive Transcriptional Elongation Factor B; Signal Transduction; T-Lymphocytes; Triazoles; Virus Activation; Virus Latency | 2015 |
Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma.
Topics: Animals; Azepines; Cell Line, Tumor; Diterpenes; DNA Replication; Herpesvirus 8, Human; Humans; Lymphoma, Primary Effusion; Mice; NF-kappa B; Oncolytic Virotherapy; Oncolytic Viruses; Sarcoma, Kaposi; Triazoles; Virus Replication; Xenograft Model Antitumor Assays | 2017 |